About the Company
Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RTTR News
Microbiomes – News and Features
Ritter Pharmaceuticals, Inc. (Ritter) announced the last patient has completed treatment in its Phase 2 study for RP-G28, a first-in-class treatment for symptoms associated with lactose intolerance.
Cumberland County hotel evacuated during overnight fire
More than one hundred rooms were evacuated during an early Wednesday fire at a Cumberland County hotel, dispatchers said. The ...
CRVS Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers ...
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Early morning Cumberland County hotel fire causes evacuations
An early morning fire forced an evacuation at a Cumberland County hotel on Wednesday. According to the Lower Allen Township ...
NRBO NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241 ...
Jason Ritter
Melanie Lynskey Says Husband Jason Ritter Constantly Re-Proposes: The First Time 'Wasn't Great' Melanie Lynskey on What Saved Her Relationship with Jason Ritter in Its 'Darkest and Most Difficult ...
Madrigal Pharmaceuticals, Inc. (MDGL)
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday ...
Catalyst Pharmaceuticals, Inc. (CPRX)
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or ...
Actinium Pharmaceuticals Inc ATNM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead ...
Loading the latest forecasts...